UK Budget good for large corporates and academia, but little for biotechs
This article was originally published in Scrip
The UK Chancellor of the Exchequer [finance minister] George Osborne assured Parliament on 21 March that he would be backing industries such as pharmaceuticals, amongst others, in an effort to reduce the dominance of the financial services industry.
You may also be interested in...
Despite claims from 'research-based' biologics manufacturers and their representatives in the EU and US that the biosimilars market is small and relatively unimportant, the age of biosimilars is clearly already upon us. A recently launched database from Datamonitor reveals a total of 556 biosimilars currently in development or being marketed globally with over 200 companies involved in the endeavour.
Mark Hollis explores developments in emerging markets and considers what their impact might be on growth.
Pharmaceutical companies are likely to be reeling today with the announcement that €2.1 billion ($2.8 billion) of healthcare spending cuts will take place during 2011–15 in Greece. These cuts will be implemented through widening the use of electronic prescribing, and drug price cuts. This will not only negatively impact pharmaceutical company sales in Greece, but also sales in other countries which reference Greek drug prices.